<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100901</url>
  </required_header>
  <id_info>
    <org_study_id>2104CLI</org_study_id>
    <nct_id>NCT05100901</nct_id>
  </id_info>
  <brief_title>Tolerance and Safety of an Oral Nutritional Supplement</brief_title>
  <acronym>Glaze</acronym>
  <official_title>Tolerance and Safety of an Oral Nutritional Supplement Containing Monoacylglycerol Oil (MAG Oil) as the Main Lipid Source in Healthy Adolescents and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, non-randomized, interventional, single arm study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective is to assess whether the MAG oil (monoacylglycerol oil) containing study&#xD;
      formula is well tolerated and safe when used as an ONS in healthy adults and adolescents.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Describe the incidence and characteristics of possible gastrointestinal intolerance&#xD;
           symptoms&#xD;
&#xD;
        2. Describe changes in stool characteristics, specifically stool frequency and consistency&#xD;
&#xD;
        3. Describe changes in anthropometric parameters, particularly weight and body mass index&#xD;
           (BMI)&#xD;
&#xD;
        4. Describe changes in blood parameters of lipid metabolism&#xD;
&#xD;
        5. Describe changes in hematological and serum biochemistry parameters&#xD;
&#xD;
        6. Describe daily ONS intake and assess dietary adherence to the study protocol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Actual">October 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>[ Time Frame: Day 2 to Day 15 ]</time_frame>
    <description>Number of subjects who develop gastrointestinal intolerance reported as adverse events related to the investigational product and leading to premature discontinuation of the study product, assessed by a daily questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of gastrointestinal intolerance symptoms</measure>
    <time_frame>[ Time Frame: Day 1 to Day 15 ]</time_frame>
    <description>Visual analog scale from 0 (no symptom) to 10 (maximum frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Assesses symptoms over the past 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>[ Time Frame: Day 1 to Day 15 ]</time_frame>
    <description>Assessed by a questionnaire for stool frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Change in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Measure of triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Measure of cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Measure of fatty acids profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes full blood count</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Number of participants with haematology measurements (erythrocyte count, thrombocyte count, haemoglobin, haematocrit, mean cell hemoglobin concentration) using immunoassays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes liver function</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Number of participants with changes in clinical chemistry (AST, ALT, ALP, GGT, albumin) using immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal function</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Number of participants with changes in clinical chemistry (urea creatine, chloride, creatine kinase, urate) using immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood glucose</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Number of participants with change in blood glucose using immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily intake of study product</measure>
    <time_frame>[ Time Frame: Day 1 to Day 15 ]</time_frame>
    <description>Number of subjects adhering to daily intake of the study product from baseline to Day 15, assessed by a daily questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>[ Time Frame: Day 1 to Day 15 ]</time_frame>
    <description>Assessed by the Bristol Stool Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Change in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat soluble-vitamins profile</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Fat soluble-vitamins (A, D, E, K)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum biochemistry parameters</measure>
    <time_frame>[ Time Frame: Day 1 and Day 15 ]</time_frame>
    <description>Number of participants with changes in serum biochemistry (triglycerides, total protein, bilirubin total, bilirubin direct, sodium, potassium, calcium, phosphate, magnesium, chloride, CRP) using immunoassays</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Oral nutritional supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral nutritional supplement that contains MAG oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MAG oil oral nutritional supplement (ONS)</intervention_name>
    <description>The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.</description>
    <arm_group_label>Oral nutritional supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  BMI range from &gt;18 to &lt;28 kg/m2 for adults with a minimum body weight of 45 kg&#xD;
&#xD;
          -  BMI range between the 25th and 90th percentile according to the Swiss growth charts&#xD;
             for adolescents with a minimum body weight of 40 kg&#xD;
&#xD;
          -  Cohort 1: Adults aged 18+ years (6 males, 6 females)&#xD;
&#xD;
          -  Cohort 2: Adolescents aged 12-17 years (6 males, 6 females)&#xD;
&#xD;
          -  Deemed able to comply with study protocol for 2 weeks&#xD;
&#xD;
          -  Able to obtain written informed consent from participants and /or legal guardians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing chronic medical or psychiatric conditions, as diagnosed by the treating&#xD;
             physician&#xD;
&#xD;
          -  Subjects taking dietary supplements (energy supplements, protein supplements) will be&#xD;
             excluded. Subjects can continue taking vitamin or herbal supplements during the study&#xD;
             period.&#xD;
&#xD;
          -  Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory&#xD;
             bowel disease (IBD), diverticular disease, colon cancer, irritable bowel syndrome&#xD;
             (IBS), history of chronic constipation with passage of fewer than 3 spontaneous bowel&#xD;
             movements per week on average, or chronic or recurrent diarrhea with loose or watery&#xD;
             bowel movements more than 3 times daily.&#xD;
&#xD;
          -  Recent episode of an acute gastrointestinal illness with significant gastrointestinal&#xD;
             symptoms in the 7 days prior to enrolment.&#xD;
&#xD;
          -  Colonoscopy or other bowel cleansing procedures within 4 weeks prior to enrolment.&#xD;
&#xD;
          -  Prior use of prescription medication(s), in particular antibiotics, antacids,&#xD;
             laxatives or other medications impacting gastrointestinal transit time, within 8 weeks&#xD;
             prior to enrolment.&#xD;
&#xD;
          -  Significant medical or surgical event in the past 3 months potentially interfering&#xD;
             with study procedures and assessments.&#xD;
&#xD;
          -  Known food allergy in particular cow's milk protein allergy (CMPA) or known&#xD;
             hypersensitivity/intolerance to any other ingredients in the study product.&#xD;
&#xD;
          -  Known alcohol or substance abuse; specifically, alcohol intake &gt; 2 servings per day. A&#xD;
             serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer.&#xD;
&#xD;
          -  Pregnant or lactating women or having given birth in the past 6 months prior to&#xD;
             enrolment.&#xD;
&#xD;
          -  Family or hierarchical relationships with Clinical Innovation Lab staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nestlé CDU / Clinical Innovation Lab</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

